Keros Therapeutics, Inc. (KROS) SEC Filings — 2025
27 SEC filings for Keros Therapeutics, Inc. (KROS) in 2025.
Filings
- Keros Swings to Profit on Soaring License Revenue, Plans $375M Capital Return — 10-Q · Nov 5, 2025
- Keros Therapeutics Files 8-K with Material Agreements and Officer Changes — 8-K · Oct 15, 2025
- Keros Therapeutics Files 8-K — 8-K · Sep 8, 2025
- Keros Therapeutics Files 8-K — 8-K · Aug 28, 2025
- Keros Therapeutics Files 8-K — 8-K · Aug 20, 2025
- Keros Therapeutics' Q2 Net Loss Widens to $45.2M Amid R&D Push — 10-Q · Aug 6, 2025
- Keros Therapeutics Files 8-K — 8-K · Jul 17, 2025
- Keros Therapeutics Announces Board and Executive Changes — 8-K · Jul 15, 2025
- Keros Therapeutics Files 8-K — 8-K · Jun 9, 2025
- Keros Therapeutics Files 8-K — 8-K · Jun 6, 2025
- Keros Therapeutics Files 8-K: Exit, Disposal, and Financials — 8-K · May 29, 2025
- Keros Therapeutics Files Proxy Statement with Glass Lewis Recommendation — DEFA14A · May 27, 2025
- Keros Therapeutics Files Proxy Statement Supplement — DEFA14A · May 19, 2025
- Keros Therapeutics Files 8-K — 8-K · May 12, 2025
- Keros Therapeutics Proxy Fight: Stockholder Withholds Votes — DEFA14A · May 9, 2025
- Keros Therapeutics Files 8-K on Operations and Financials — 8-K · May 6, 2025
- Keros Therapeutics Files Definitive Proxy Statement — DEF 14A · Apr 23, 2025
- Keros Therapeutics Enters Material Definitive Agreement — 8-K · Apr 18, 2025
- Keros Therapeutics Enters Material Agreement — 8-K · Apr 10, 2025
- Keros Therapeutics Files 8-K — 8-K · Mar 31, 2025
- Keros Therapeutics Files 8-K for Bylaw Amendments — 8-K · Mar 6, 2025
- Keros Therapeutics Files 8-K — 8-K · Feb 28, 2025
- Keros Therapeutics, Inc. 10-K Filing — 10-K · Feb 26, 2025
- Keros Therapeutics Files 8-K — 8-K · Jan 30, 2025
- Keros Therapeutics Files 8-K — 8-K · Jan 21, 2025
- Keros Therapeutics Files 8-K — 8-K · Jan 15, 2025
- Keros Therapeutics Files 8-K — 8-K · Jan 10, 2025